Basic Information
PIQRAY 250MG DAILY DOSE PACK (200mg + 50mg)
TABLET, FILM COATED
Regulatory Information
SIN15916P
March 25, 2020
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
Company Information
NOVARTIS (SINGAPORE) PTE LTD
NOVARTIS (SINGAPORE) PTE LTD
Active Ingredients
Alpelisib (in Light Pink Tablet)
Strength: 50mg
Alpelisib (in Light Red Tablet)
Strength: 200mg
Detailed Information
Contraindications
**5 Contraindications** Piqray is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.
Indication Information
**3 Indications** Piqray® is an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor indicated for the treatment of postmenopausal women, and men, with hormone receptor positive, HER2- negative, advanced breast cancer with a PIK3CA mutation in combination with fulvestrant after disease progression following an endocrine-based regimen.